Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhejiang Taimei Medical Technology Co., Ltd.
浙江太美醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2576)

SUPPLEMENTAL ANNOUNCEMENT
DISCLOSEABLE TRANSACTION
FORMATION OF PARTNERSHIP

Reference is made to the announcement of the Company dated December 24, 2025 (the "**Announcement**") regarding the discloseable transaction in relation to formation of Partnership. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

The Company wishes to provide Shareholders and potential investors with the following supplemental information to the Announcement.

REASONS FOR SETTING THE INITIAL TOTAL CAPITAL CONTRIBUTION OF THE PARTNERSHIP AT RMB227.27 MILLION

The initial total capital contribution of RMB227.27 million was jointly determined by all partners through arm's length negotiations based on the following commercial and legal factors:

(1) As disclosed in the Announcement, the Partnership will hold pipeline interests and participate in early-stage clinical trials of new drugs before such pipelines are disposed of or transferred as an exit of the relevant investment. Based on the typical average cost structure for Phase I clinical trial for new drug development in China, the average cost of a Phase I clinical trial is approximately US$5 million. Based on the investment strategy and capital requirement estimations, and taking into account the industry knowledge and investment experience of the Fund Manager as well as the currently available investment opportunities, it is anticipated that the Partnership will initiate approximately five to six

investment projects in the healthcare industry. As the investment in any single project shall not exceed 20% of the total initial capital contribution, the Partnership requires investable capital of over RMB200 million to cover the initial and subsequent investment rounds for these high-quality projects; and

(2) A total scale of RMB227.27 million satisfies the investment needs while avoiding the presence of idle funds. The specific amount was agreed upon by the partners based on their respective resource endowments, risk appetite, and strategic positioning.

REASONABLENESS OF THE PROPORTION OF CONTRIBUTION BY THE GROUP IN THE PARTNERSHIP

The Group (which includes the Company and Taimei Intelligence) collectively contributes approximately 44.00% (amounting to RMB100 million) of the total capital contribution. Such proportion and amount were prudently determined based on the following factors:

(1) Strengthening industrial synergy rather than financial control: The core objective of the Group's participation in the Partnership is to construct an "AI + Clinical Research + Investment" ecosystem closed-loop. The investment focus of the Fund Manager aligns with the Company's interests in frontier technologies and complements the Company's years of experience in pharmaceutical R&D digitalization technologies and clinical development outsourcing services. By supporting investee companies through technology empowerment, CRO services, and data platforms, the Group aims to achieve asset-light synergistic effects. A high ownership percentage is not a necessity, and the current proportion is sufficient to secure priority access to projects and commercial collaboration opportunities;

(2) Alignment with local industrial fund: Jiaxing Industrial Fund, representing the local government industrial guiding fund, intends to contribute RMB100 million to the formation of the Partnership, with an aim to attract high-quality biopharmaceutical projects to settle in Jiaxing. Based on the consensus and recognition of the cooperation prospects, the Company and Jiaxing Industrial Fund are willing to commit an equal proportion of capital; and

(3) Fair and transparent distribution mechanism: The Partnership adopts a standard distribution structure, where the return of capital is followed by a 6% per annum Threshold Profit, and then the distribution of excess returns is based on actual contribution proportions. The Group enjoys identical economic rights as other limited partners without any preference or tilt in interests.

The total capital contribution and the Group's proportion of contribution are based on genuine commercial substance, a balance between risks and returns, and industrial synergy effects, which are determined through market-oriented negotiations with commercial reasonableness.

The capital contribution of each partner was determined having regard that the Fund Manager has the expertise and experience in investments in biopharmaceutical field and will provide advice to the Partnership in identifying investment target, and after arm's length negotiations among the partners. To the best knowledge, information and belief of the Directors, after having made reasonable enquiries, the Fund Manager focuses on investments in the two major sectors of TMT and healthcare, with a business network covering China, North America, Europe and other regions, managing an aggregate scale of more than RMB5 billion and having provided capital and resources support to more than a hundred of investment projects, including 17 companies listed on the Shanghai Stock Exchange, the Shenzhen Stock Exchange, the Stock Exchange or NASDAQ.

In view of the above, the Board is of the view that the basis of determining the initial capital contribution of the Company and Taimei Intelligence to the Partnership is fair and reasonable.

As at the date of this announcement, the Partnership has not identified any potential investment targets and thus the Partnership does not have any concrete plan for the usage of the capital contribution to the Partnership.

Save as the supplemental information as disclosed above, all other information contained in the Announcement remains unchanged.

By order of the Board
Zhejiang Taimei Medical Technology Co., Ltd.
Mr. ZHAO Lu
Chairman of the Board

Hong Kong, February 15, 2026

As at the date of this announcement, the Board comprises Mr. ZHAO Lu, Mr. MA Dong, Mr. ZHANG Hongwei, Mr. LU Yiming, Mr. HUANG Yufei and Ms. NI Xiaomei as executive Directors, and Dr. JIANG Xiao, Dr. LI Zhiguo and Mr. FUNG Che Wai Anthony as independent non-executive Directors.